Aug. 9 at 7:48 PM
$CABA 🚀🧬
One of the BIGGEST reasons I’m bullish is WHO is behind this company.
Dr. Michael Milone, a Cabaletta co-founder, was a co-inventor of CTL019 — the CAR-T therapy that became Kymriah, the first FDA-approved CAR-T treatment.
Dr. Carl June, a pioneer who helped develop the CAR-T platform at Penn, is connected to Cabaletta through its Scientific Advisory Board.
Gwendolyn Binder worked at Penn on engineered T-cell programs, including the CD19 CAR program that became Kymriah.
Think about that. 🤯
People directly involved in CAR-T technology that changed cancer treatment are now applying that same technology to autoimmune disease.
They’re not starting from scratch. They’re taking technology they helped prove in cancer and aiming it at a MASSIVE autoimmune market. 🧬🔥
If Big Pharma sees what I see, a
$1.5B+ buyout isn’t far-fetched. We could wake up one morning to a deal putting
$CABA around
$15/share. 🚀
The market is sleeping on this one!!! 🚀
